Abstract
We conducted a multi-center study to analyze factors predicting survival among patients with TP53-mutated (m) AML receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) in the recent era. Out of 370 TP53m AML patients, 68 (18%) patients were bridged to allo-HSCT. The median age of the patients was 63 years (range, 33–75), 82% of patients had complex cytogenetics and 66% of patients had multi-hit TP53m. Forty three percent received myeloablative conditioning and 57% received reduced intensity conditioning. The incidence of acute graft versus host disease (GVHD) was 37% and chronic GVHD was 44%. The median event-free survival (EFS) from the time of allo-HSCT was 12.4 months (95% CI: 6.24–18.55) and median overall survival (OS) was 24.5 months (95% CI: 21.80–27.25). In multivariate analysis utilizing variables that showed significance in univariate analysis, complete remission at day 100 post allo-HSCT retained significance for EFS (HR: 0.24, 95% CI: 0.10–0.57, p = 0.001) and OS (HR: 0.22, 95% CI: 0.10–0.50, p ≤ 0.001). Similarly, occurrence of chronic GVHD retained significance for EFS (HR: 0.21, 95% CI: 0.09–0.46, p ≤ 0.001) and OS (HR: 0.34, 95% CI: 0.15–0.75, p = 0.007). Our report suggests that allo-HSCT offers the best opportunity to improve long-term outcome among patients with TP53m AML.
Original language | English (US) |
---|---|
Pages (from-to) | 799-806 |
Number of pages | 8 |
Journal | Leukemia |
Volume | 37 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2023 |
Funding
TB: Received Mayo Clinic Cancer Center Support Grant (P30 CA015083), serve in advisory board for Pfizer and Takeda AP: Consulting for Abbvie, research funding from Kronos Bio, Pfizer, Celgene/BMS, Servier, VK: Advisory board for Novartis and Pfizer, MS: Consulting for Curis Oncology, advisory board for Novartis, Kymera, Sierra Oncology, participated in GME activities for Novartis, Curis Oncology, Haymarket and Clinical Care Options.
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research